<< Back To Search

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT02693535
Age 12 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients. The study focuses on using a specific type of drug that targets the cancer cells in a unique way. This method aims to improve the effectiveness of treatment while reducing side effects. Here are some key points about the study:
  • The treatment involves a combination of drugs that work together to attack the cancer cells more effectively.
  • It includes a specific type of drug that has shown promise in previous studies, making it a potentially powerful option for patients.
  • The study is designed to evaluate how well this new treatment works compared to standard therapies.
  • Patients will be closely monitored throughout the study to assess their response to the treatment and any side effects they may experience.
  • This approach may offer a new hope for patients who have not responded well to existing treatments.
Overall, this study represents an innovative effort to enhance treatment options and improve outcomes for patients. By focusing on a targeted approach, researchers hope to provide a more effective and personalized treatment plan.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: